Reducing severe cutaneous
adverse and type B adverse drug reactions using pre-stored HLA
genotypes
Running title: Preemptive HLA typing and adverse drug reactions
Kye Hwa Lee1,
Kang Dong Yun2 · Hyun Hwa
Kim2 · Yi Jun Kim3· Hyo Jung Kim4 · Ju Han
Kim4 · Eun Young Song5,
James Yun MD6,7, Hye-Ryun Kang2,8*
1Department of Information Medicine, Asan Medical
Center, Seoul 05505, South Korea
2Drug Safety
Center, Seoul National University Hospital, Seoul 03080, South Korea
3Institute of Convergence Medicine, Ewha Womans
University Mokdong Hospital 07984, Seoul, Korea
4Seoul National University Biomedical Informatics and
Systems Biomedical Informatics Research Center, Division of Biomedical
Informatics, Seoul National University College of Medicine, Seoul 03080,
South Korea
5Department of Molecular Medicine and
Biopharmaceutical Sciences, Graduate School of Convergence Science and
Technology and College of Medicine, Medical Research Center, Seoul
National University, Seoul 03082, South Korea
6Department of Immunology and Rheumatology, Nepean
Hospital, Sydney, Australia
7 Faculty of Medicine and Health, the University of
Sydney, Sydney, Australia
8Institute of Allergy and Clinical Immunology, Seoul
National University Medical Research Center, Seoul National University
College of Medicine, Seoul 03080, South Korea
*Corresponding Author: Hye-Ryun
Kang, MD, PhD
Department of Internal Medicine, Seoul National University Hospital, 101
Daehak-ro, Jongno-gu, Seoul 03080, South Korea
Tel no.: +82-2-2072-0820
Fax no.: +82-2-742-3291
Email: helenmed@snu.ac.kr